NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis

Agios Pharmaceuticals, Inc. (AGIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AGIO

$33.10

−$0.03 (−0.09%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AGIO with… →

AGIO Key Statistics

As of Sep 4, 2026
Trading
Open
$33.13
Previous Close
$33.13
Day's Range
32.92–33.50
52-Week Range
22.24–46.00
Volume
480.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$1.98B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.10
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.01
Financials (FY)
Revenue (FY)
$54.03M+48.03%
Net Income (FY)
−$412.78M−161.27%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.70M
1-Year Return
−8.39%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.15M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AGIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+21.60%
2025−17.16%
2024+47.55%
2023−20.69%
2022−14.57%
2021−24.14%
2020−9.26%
2019+3.56%
2018−19.35%
2017+37.00%
2016 (partial year)+2.71%

As of September 4, 2026.

AGIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$54.03M−$412.78M−764.0%
2024$36.50M$673.73M1845.9%
2023$26.82M−$352.09M−1312.6%
2022$14.24M−$231.80M−1627.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$54.03M$47.68M−$472.13M−$412.78M−764.0%
2024$36.50M$32.33M−$425.74M$673.73M1845.9%
2023$26.82M$23.94M−$391.49M−$352.09M−1312.6%
2022$14.24M$12.54M−$389.05M−$231.80M−1627.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AGIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricAGIOBiotechnology medianvs median
P/S ratio20.1015.2632% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Agios Pharmaceuticals, Inc. (AGIO) carries a market capitalisation of $1.98B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 539 employees.

The 52-week range on file runs from $22.24 to $46.00. The most recent close on file for AGIO is $33.10, dated September 4, 2026. That is −$0.03 (−0.09%) against the previous close. The latest close sits 48.83% above that 52-week low.

Financial Health

In fiscal 2025, Agios Pharmaceuticals, Inc. reported revenue of $54.03M. That is +48.03% against the prior fiscal year, when revenue was $36.50M. The same year closed with a net loss of $412.78M. The reported profit margin is 0%. Trailing earnings per share are −7.01.

Across the 4 fiscal years on file, revenue moves from $14.24M in 2022 to $54.03M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 20.1 times revenue. On price-to-sales that is 31.66% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.6. Annualized volatility over the trailing 10 years is 56.94%. The trailing one-year price return is −8.39%. Measured over 10 years, that is −0.93% a year compounded.

Growth & Income

No dividend is on file for AGIO.

The strongest complete calendar year on file is 2024 at +47.55%; the weakest is 2021 at −24.14%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +21.60% year to date.

Peer Comparison

Agios Pharmaceuticals, Inc. (AGIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Agios Pharmaceuticals, Inc. AGIO $1.98B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Agios Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Visit website →